How's Mesoblast doing these days?
In our cell therapy market deck, you will find everything you need to understand the market
SUMMARY
How's Mesoblast doing these days? Mesoblast looks meaningfully healthier than its old reputation suggests, because Ryoncil has turned the company from a long-running biotech promise into a commercial-stage business with real revenue, reimbursement progress, and several credible follow-on shots.
The biggest change is that Mesoblast is no longer asking investors to believe only in future approvals. Ryoncil has already produced US$30.3 million of net revenue in the March 2026 quarter, and first-year launch revenue is now approaching US$100 million.
The launch signal looks more durable than a one-time stocking event. Transplant-center onboarding kept expanding after approval, moving from 32 centers to 45, then 49, with a 64-center target covering 94% of U.S. transplant volume.
Reimbursement has quietly become one of the most important pieces of the story. The permanent CMS J-code J3402, broader payer coverage, and mandatory fee-for-service Medicaid coverage reduce the billing uncertainty that can choke expensive hospital therapies.
Ryoncil’s price is clearly high, but the early market response says the price has not broken adoption. That is partly because pediatric steroid-refractory acute GVHD is rare, severe, hospital-managed, and easier to justify economically than a broad chronic condition.
The financial profile is no longer as fragile as before. Mesoblast generated US$34.6 million of customer receipts in the March 2026 quarter, cut net operating cash spend to US$4.1 million, and ended with US$122 million of cash.
Adult GVHD is the cleanest near-term expansion because it builds on the existing Ryoncil machine. Mesoblast already has transplant-center relationships, pediatric approval, manufacturing history, and a trial design that adds Ryoncil to ruxolitinib instead of fighting current practice head-on.
The pipeline now has more substance, but also more funding pressure. Chronic low back pain has an enrolled pivotal Phase 3 trial, DMD has an IND-cleared registrational path, and CAR-MSC gives the platform story a more modern engineering angle.
The competitive setup is helpful but not empty. Ryoncil has pediatric orphan exclusivity and first-approved MSC status in the U.S., while adult GVHD still runs through Jakafi and future transplant approaches like Orca-T could change the market later.
The governance and financing moves fit a company moving from survival mode to commercial execution. New board roles, a chair transition, and insider-backed refinancing suggest Mesoblast now needs capital discipline and partnership leverage more than pure clinical storytelling.
The main risk is that Mesoblast tries to do too much before Ryoncil becomes large enough to fund the next phase. The turnaround looks real, but it still depends on Ryoncil continuing to scale while adult GVHD, chronic low back pain, DMD, and CAR-MSC mature.
So the current answer is fairly clear: Mesoblast is doing much better than before, but it is not yet de-risked. Ryoncil has changed the company’s credibility, and the next test is whether that first commercial wedge can support a broader, more expensive pipeline.
This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Is Mesoblast actually making money with Ryoncil these days?
Mesoblast is finally looking like a company with a real commercial product, not just a biotech story waiting for approval.
The important part is not just that Ryoncil is approved. Everyone knows that by now. The stronger signal is that the launch is already showing repeat orders, real billing, and a revenue rhythm. Ryoncil did US$30.3 million of net revenue in the March 2026 quarter, after roughly US$30 million of gross revenue in the previous quarter, and Mesoblast says first-year launch revenue is now approaching US$100 million.
That matters because this is a tiny, hospital-based, ultra-specialty indication. A product like this does not need thousands of patients to become meaningful. If a few dozen children completing therapy can already support this kind of revenue, then Mesoblast has found a high-value commercial wedge.
Actually, Ryoncil is starting to pay for the next version of Mesoblast. The company cut net operating cash spend to US$4.1 million in the March quarter and ended with US$122 million of cash.
So today, Mesoblast has a product that can help fund that pipeline.
If you want more recent data on this point, please see our latest cell therapy market report.
Is Ryoncil still getting used, or was the launch just a first spike?
Ryoncil still looks like it is getting pulled into transplant-center workflow.
We would be more cautious if revenue had come from a one-time stocking wave. But the center-onboarding signal says something more practical is happening. Mesoblast had 32 U.S. transplant centers onboarded after the early launch, then 45 centers by January 2026, then 49 centers by the February update, with a target of 64 centers covering 94% of U.S. transplant volume.
That is a useful signal because the bottleneck in this market is not consumer demand. It is whether pediatric transplant teams can identify eligible children, order the product, get coverage, and use it early enough. The fact that onboarding kept moving after launch tells us Mesoblast is still expanding the treatment channel, not just monetizing the first excited sites.
The real-world survival update also helps. Of the first 25 children treated commercially, 21 were alive and completed the initial 28-day regimen. It is a small number, but it is exactly the type of post-launch signal we want here: real patients, real hospitals, actual treatment completion.
As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily
Is Mesoblast getting paid smoothly for Ryoncil now?
Mesoblast has made reimbursement much less scary than it was six months ago.
The biggest fresh signal is the permanent CMS J-code J3402, active from October 1, 2025. That sounds administrative, but for a US$194,000-per-infusion hospital product, it is huge. Hospitals hate financial ambiguity. A clean product-specific code makes it easier to bill Medicaid and pushes commercial payers to update their systems too.
The coverage numbers are also moving in the right direction. Mesoblast reported coverage across roughly 260 million U.S. lives in January, then around 280 million U.S. lives by the February half-year update, alongside mandatory fee-for-service Medicaid coverage across U.S. states. That is the boring plumbing behind the revenue line.
There is still friction. Prior authorization criteria exist, and no payer wants high-cost cell therapies to become casual prescribing. But today, the evidence says reimbursement is becoming a launch accelerator for Mesoblast, not the main launch blocker.
If you want more recent data on this point, please see our latest cell therapy market report.
Is Mesoblast still burning cash like before?
Mesoblast is much less financially fragile now, although it still has to spend carefully.
The March 2026 quarter changed the tone. Mesoblast generated US$34.6 million of customer receipts, reported US$30.3 million of net Ryoncil revenue, and kept net operating cash spend to US$4.1 million. For a company that used to be valued mostly on future approvals, that is a very different setup.
The debt move matters too. In December 2025, Mesoblast replaced its old Oaktree senior debt with a five-year credit line of up to US$125 million, initially drawing US$75 million, at a fixed 8% interest rate. The facility also left material assets and IP unencumbered, which gives Mesoblast more room to negotiate partnerships.
Mesoblast now has more shots on goal than a small company can casually fund forever. Adult GVHD, DMD, chronic low back pain, heart failure, IBD, and CAR-MSC work all compete for attention. The balance sheet is healthier, but Mesoblast still needs Ryoncil to keep climbing so the pipeline does not eat the turnaround.
This chart, featured in our cell therapy market deck, shows annual VC investment in cell therapy startups
Is adult GVHD becoming the next big thing for Mesoblast now?
Adult GVHD is the most believable next Ryoncil expansion for Mesoblast.
The reason is simple: Mesoblast is not trying to invent a totally new market here. It already has the pediatric approval, the manufacturing file, the transplant-center relationships, and early real-world use. Now it wants to move into adults, where the company says the population is roughly three times larger than pediatric SR-aGVHD.
The trial design is also more realistic than a “we will replace the standard of care” story. The NIH-funded BMT CTN trial compares ruxolitinib alone versus ruxolitinib plus Ryoncil, started early after steroid refractoriness. That is smart because Jakafi is already embedded in the field. Mesoblast is trying to sit on top of that pathway rather than pretend doctors will abandon it overnight.
The survival context is what makes the angle worth watching. In adults who fail ruxolitinib, survival can be as low as 20% to 30% by Day 100, while Mesoblast has pointed to 76% Day-100 survival in expanded-access patients aged 12 and older who had failed ruxolitinib or other second-line agents.
We would not overread that as randomized proof, but it explains why the adult trial could matter quickly if enrollment starts cleanly.
If you want more recent data on this point, please see our latest cell therapy market report.
Is Mesoblast getting lucky with competitors lately?
Mesoblast is getting some help from the competitive landscape, but the market is not empty.
In pediatric SR-aGVHD, Ryoncil has a very good near-term position. It is FDA-approved for children, it has orphan exclusivity, and it is the first approved MSC product in the U.S. That gives Mesoblast time to build the channel before a direct pediatric MSC rival shows up.
The adult and broader GVHD world is busier. Incyte’s Jakafi is still a monster product, with US$758 million of Q1 2026 net sales across indications, so any adult GVHD expansion has to work around ruxolitinib rather than ignore it. That is why Mesoblast’s add-on trial design looks sensible.
Two weaker signals also help Mesoblast at the margin. MaaT Pharma’s acute-GVHD microbiome therapy received a negative-trend opinion from EMA’s CHMP in May 2026, which slows the clean “new GVHD challenger” story in Europe. Orca Bio’s Orca-T is more about improving transplant outcomes and reducing GVHD upfront, with its FDA review extended to July 2026 after a CMC-related amendment. That could reshape transplant practice later, but it does not look like an immediate Ryoncil substitute today.
This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
Is Mesoblast’s Ryoncil price causing problems now?
Mesoblast’s Ryoncil price is high, but the early signals say hospitals are still using it.
Ryoncil’s wholesale acquisition cost is US$194,000 per infusion, and the approved regimen is twice weekly for four weeks. So this is obviously not a casual drug order. The whole launch depends on whether the clinical severity and survival benefit make the economics acceptable to hospitals and payers.
So far, the market is not rejecting it. Revenue reached about US$100 million in the first launch year, coverage expanded to hundreds of millions of U.S. lives, and the J-code removed one of the biggest billing headaches. That combination tells us the price is painful, but not commercially fatal.
The hidden point is that the indication helps Mesoblast. Pediatric steroid-refractory acute GVHD is rare, severe, and hospital-managed. That makes a very expensive product easier to justify than it would be in a broad chronic condition. The pricing debate becomes much harder if Mesoblast tries to move the same economic logic into bigger, less acute markets.
Is chronic low back pain still a real upside for Mesoblast?
Mesoblast’s chronic low back pain program is real again, mostly because the trial finally reached the point where data can answer the question.
For years, this sounded like the classic huge-market biotech promise: degenerative disc disease, millions of patients, opioid-sparing potential, blockbuster math. The fresh signal is more concrete. In April 2026, Mesoblast said its pivotal Phase 3 trial in chronic low back pain hit the 300-patient recruitment target, with a 12-month pain-reduction endpoint and top-line data expected around mid-2027.
That changes the quality of the bet. We are no longer judging a theoretical market slide but rather waiting on a controlled, sham-comparator trial that could support a BLA under RMAT if the data hold. The FDA also gave clearer feedback that 12-month pain reduction can be an approvable endpoint, which reduces one big regulatory ambiguity.
Still, this is the riskiest “big upside” in the story. Low back pain is a messy market with subjective endpoints, placebo effects, procedure economics, and reimbursement skepticism. If Mesoblast wins here, the upside is enormous. If it misses, the market will probably compress the pipeline story back toward Ryoncil and adult GVHD.
If you want more recent data on this point, please see our latest cell therapy market report.
This chart, featured in our cell therapy market deck, shows annual funding in cell therapy startups
Is Mesoblast suddenly serious about DMD?
Mesoblast is taking DMD seriously now, but this is still an early bet.
The fresh signal is the April 2026 FDA IND clearance for Ryoncil to go directly into a registrational trial in Duchenne muscular dystrophy. The trial is planned for 76 boys aged 5 to 9, using seven infusions over nine months, with time-to-stand at nine months as the primary endpoint. That is much more concrete than “we may explore DMD one day.”
The reason this is interesting is that Mesoblast can reuse some parts of the Ryoncil machine: pediatric safety experience, rare-disease messaging, and a hospital-specialty commercial mindset. DMD also gives Mesoblast a larger pediatric rare-disease market than pediatric GVHD, with around 15,000 U.S. children affected.
But we should stay strict here. IND clearance is permission to test, not proof that Ryoncil works in DMD. Also, Mesoblast had to correct an April 2026 release to avoid implying endorsement by Parent Project Muscular Dystrophy. That is a small but useful signal: the company is pushing into a sensitive disease community where wording, advocacy relationships, and evidence standards matter a lot.
Is Mesoblast still only a first-generation MSC story?
Mesoblast is trying to move beyond old-school MSCs, and the CAR-MSC move is the clearest signal.
The April 2026 acquisition of Mayo Clinic-developed CAR-MSC technology is more interesting than it first looks. Mesoblast already has the first approved MSC product in the U.S., but the criticism around MSCs has always been potency, targeting, and consistency. Adding CAR technology is basically Mesoblast saying: we need engineered cells that can go more precisely where inflammation is happening.
The deal structure also matters. Mesoblast obtained worldwide exclusive rights, and Mayo Clinic is expected to support GMP manufacturing work. That is not enough to validate the platform, but it gives Mesoblast a credible way to refresh the science story without abandoning the approved-product base.
So today, the platform story is stronger than before. Ryoncil proves the company can get an allogeneic MSC product approved and sold. CAR-MSC is the attempt to make the next products more targeted, more patentable, and potentially more compelling to partners.
If you want more recent data on this point, please see our latest cell therapy market report.
This chart, featured in our cell therapy market deck, compares the main business model options for cell therapy biotech companies
Is Mesoblast’s leadership acting like the company has changed?
Mesoblast’s leadership and board moves do look like a company shifting from survival mode to commercial execution.
The most visible change is governance. Gregory George, Mesoblast’s largest shareholder, joined the board in 2025. Lyn Cobley, a senior banking and finance executive, also joined. Then Philip Facchina became Chair from January 2026. Around the same time, the company refinanced with a credit facility provided by Dr. George.
That cluster of moves says something. Mesoblast now needs commercial discipline, market-access execution, capital allocation, and partnership leverage more than pure clinical storytelling. The board composition is catching up with that phase.
There is one watch item. A credit facility from a major shareholder and director is not automatically bad, especially if the terms are better and non-dilutive. But it does create related-party optics.
For now, the result looks positive because Mesoblast lowered financing pressure and freed up IP flexibility. We would still watch whether future financing or partnerships stay clean and shareholder-friendly.
Is the old Mesoblast litigation overhang still relevant?
Mesoblast’s old class-action overhang looks much less relevant to today’s story.
The key litigation signal is that the Australian shareholder class action tied to older disclosure issues was resolved in 2024, subject to court approval, with the settlement funded entirely by insurers and no admission of liability. That does not erase the history, but it does mean the legal overhang is no longer the main thing driving the investment case.
The more important point is that Mesoblast has changed the evidence base. In the old version of the story, investors had to rely heavily on management claims about regulatory paths and platform potential. Today, they can look at FDA approval, real commercial sales, CMS reimbursement, actual treated patients, and active pivotal trials.
So the litigation history still matters as a reminder: Mesoblast has disappointed before, and management communication should be checked carefully. But these days, the company is less exposed to pure narrative risk because more of the story is now measurable.
This chart, featured in our cell therapy market deck, shows how market revenue is split across customer segments in the cell therapy market
How’s Mesoblast doing these days?
Mesoblast looks much healthier now than its old reputation suggests.
The company finally has what it lacked for years: an approved product that is producing real revenue, getting reimbursed, and being used in the field. Ryoncil is not a giant product yet, but it has already changed the company’s financial position and credibility. The best recent signals all point in the same direction: revenue near US$100 million in the first launch year, transplant-center onboarding still expanding, CMS billing friction falling, cash burn improving, and a cleaner debt setup.
The more interesting part is that Mesoblast now has several real follow-on shots instead of one fragile story. Adult GVHD is the most believable near-term expansion. Chronic low back pain has moved from “huge market slide” to enrolled pivotal trial. DMD is newly opened through an IND-cleared registrational path. CAR-MSC gives the platform story a more modern angle.
The main risk is that Mesoblast may now try to do too much at once. Ryoncil has given the company breathing room, not unlimited room. If adult GVHD starts enrolling well and Ryoncil keeps growing, the company’s turnaround becomes much harder to dismiss. If Ryoncil plateaus before the big trials read out, investors will quickly go back to asking whether the pipeline is too expensive for the revenue base.
| Question | Answer | Signals we checked |
|---|---|---|
| Is Mesoblast making money now? | Yes. Mesoblast finally has a real commercial revenue engine. | Ryoncil net revenue of US$30.3M in March quarter; first-year revenue approaching US$100M; US$4.1M net operating cash spend; US$122M cash. |
| Is Ryoncil still getting used? | Yes. The launch still looks active, not one-off. | 32 to 45 to 49 centers onboarded; 64-center target covers 94% of transplant volume; 84% of first 25 commercial patients alive and completed 28-day regimen. |
| Is Mesoblast getting paid smoothly? | Mostly yes. Reimbursement is becoming easier. | CMS J-code J3402 active Oct. 2025; coverage expanded from about 260M to 280M lives; Medicaid coverage across states; prior authorization still exists. |
| Is Mesoblast still cash-fragile? | Much less than before. | US$34.6M customer receipts; US$4.1M net operating cash spend; US$125M five-year credit line; old Oaktree debt repaid. |
| Is adult GVHD the next leg? | Yes. It is the most believable expansion. | NIH-funded BMT CTN trial; ruxolitinib-plus-Ryoncil design; adult market about 3x pediatric; expanded-access survival signal. |
| Is competition helping Mesoblast? | Somewhat. Mesoblast has room, but not a free market. | Ryoncil orphan exclusivity; Jakafi US$758M Q1 sales; MaaT negative-trend EMA opinion; Orca-T FDA review extension. |
| Is Ryoncil’s price a problem? | Not yet. The market is absorbing it. | US$194K per infusion; revenue near US$100M first year; J-code support; broad payer coverage; rare severe hospital indication. |
| Is chronic low back pain real? | Yes, but the data still have to prove it. | 300-patient Phase 3 recruitment complete; 12-month pain endpoint; RMAT path; mid-2027 readout expected. |
| Is DMD serious now? | Yes, but still early. | April 2026 FDA IND clearance; 76-patient registrational trial; time-to-stand endpoint; PPMD wording correction. |
| Is Mesoblast upgrading the platform? | Yes. CAR-MSC makes the platform story fresher. | Mayo-developed CAR-MSC acquisition; worldwide exclusive rights; planned GMP support; targets old MSC concerns around targeting and potency. |
| Is leadership changing with the company? | Yes. Governance now looks more commercial and finance-led. | Gregory George board role; Lyn Cobley board role; Philip Facchina chair transition; insider-backed refinancing. |
| Is old litigation still a big issue? | Less now. It is history, not the current driver. | 2024 class-action resolution; insurer-funded settlement; no admission of liability; current story now backed by sales, reimbursement, and trials. |
This chart, featured in our cell therapy market deck, shows how CAR-T cell therapy technology has evolved over time
OUR METHODOLOGY
This analysis tests how Mesoblast is doing today by separating the old biotech narrative from the newer commercial-stage evidence around Ryoncil. We focused on whether the company now has real revenue, repeat usage, workable reimbursement, a healthier cash position, and credible follow-on programs.
We did not rely on intuition, market sentiment, or broad biotech “vibe” reasoning. We broke the question into the dimensions that actually determine whether the Mesoblast story has changed: Ryoncil sales, repeat usage, reimbursement, cash position, adult GVHD expansion, competitive pressure, pricing, pipeline credibility, platform evolution, governance, and legacy risk.
For each dimension, we looked at the freshest concrete signals available and prioritized first-hand company disclosures, regulatory documents, reimbursement materials, and authoritative competitor updates. We then aggregated those signals before forming a view, rather than treating any single datapoint as decisive.
We used revenue and customer receipts to test commercial traction, transplant-center onboarding to test real-world adoption, payer coverage and CMS coding to test reimbursement friction, and trial design or regulatory milestones to separate credible pipeline progress from early optionality.
When discussing Ryoncil’s launch, we treated net revenue, customer receipts, transplant-center onboarding, patient-treatment completion, payer coverage, and the CMS J-code as the most important commercial signals. These are more useful than approval status alone because they show whether the product is actually moving through hospitals and payment systems.
When discussing the pipeline, we gave more weight to programs with concrete regulatory or clinical milestones. That is why adult GVHD, chronic low back pain, DMD, and CAR-MSC are treated differently: each has a different level of evidence, timing, and execution risk.
When discussing competition, we focused on products and companies that could affect GVHD treatment pathways or transplant-center behavior. That includes Jakafi’s current role in GVHD, MaaT Pharma’s regulatory update, and Orca Bio’s Orca-T review timeline.
That structured aggregation is what makes the final answer clearer. Mesoblast looks meaningfully healthier than its old reputation suggests, but the strength of the story still depends on whether Ryoncil keeps scaling while the next clinical programs mature.
We are not affiliated with Mesoblast, do not hold shares in the company, and have not been paid or instructed by the company. This page is independent editorial research. It is not investment advice, and it should not be read as a recommendation to buy, sell, or hold any security.
Key sources used for this analysis include: FDA approval of Ryoncil for pediatric steroid-refractory acute GVHD, FDA approved-drug page for remestemcel-L-rknd / Ryoncil, FDA Ryoncil package insert / prescribing information, Ryoncil HCP prescribing information, Ryoncil billing and coding guide, CMS HCPCS quarterly update page, CMS October 2025 HCPCS quarterly update reminder, CMS HCPCS application summary for Ryoncil, Mesoblast real-world commercial Ryoncil experience, 84% survival update, Mesoblast 2025 annual report, Mesoblast Ryoncil 7-year orphan-drug exclusivity announcement, Mesoblast March 2026 quarter Ryoncil sales release, Mesoblast chronic low back pain pivotal trial document, Mesoblast DMD IND clearance announcement, Incyte Q1 2026 financial update, including Jakafi sales, MaaT Pharma CHMP negative-trend opinion update, Orca Bio FDA review extension for Orca-T, and FDA BLA process background.
In our cell therapy market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- How strong is fundraising in the cell therapy market right now?
- Which companies have raised the most funding in the cell therapy market?
- Which companies are the most valued in the cell therapy market?
- Cell Therapy: who are the top startups?
- How's Legend Biotech doing these days?
